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T cells, CD4
ϩ T cells, and antibodies that recognize antigens expressed by the tumor (1). Methods using tumor-specific T cells or antibodies demonstrated that the molecular nature of these antigens seems to result from mutant or aberrantly expressed proteins (2) (3) (4) . Many of the genetic changes leading to the expression of these antigens seem to occur early during tumor growth (5, 6) . Furthermore, detection of these existing tumor antigens has diagnostic and therapeutic potential (7) .
However, genetic changes also seem to govern tumor progression during later stages of tumor growth (8) , namely, by generating new subpopulations that can invade, metastasize, grow more rapidly, and͞or become more resistant to previous treatments (9) . Because progression does necessarily not correlate with the loss of antigenicity (10, 11) , new genetic changes may also generate new proteins that may be recognized by the immune system. Currently, it remains unclear whether, when, and how antibodies in a tumor-bearing host respond to the antigenic byproducts of these new genetic changes. Such responses could be influenced by ''preexisting'' immune responses against other tumor antigens and͞or T cell immunodeficiencies that have been reported in cancer patients and tumor-bearing animals (1, 12, 13) .
To determine whether tumor-bearing hosts generate antibodies against new tumor antigens, we applied a tamoxifen (TAM) regulated Cre-loxP recombination system, MerCreMer (14, 15) , to induce antigens in an established tumor. Once induced, these antigens elicited high titer IgG antibody responses within 3 wk. By analogy, new antibody responses arising in cancer patients may help identify and track genetic changes occurring in a progressing tumor, thereby enabling therapies to be tailored to these new antigenic variants.
Materials and Methods
Mice, Cell Lines, and Reagents. C57BL͞6-TgN(ACTbEGPF)Osb (enhanced GFP, EGFP) transgenic mice and B6.129S7-Rag1 tm1Mom (Rag1 Ϫ/Ϫ ) mice were purchased from The Jackson Laboratory. (BALB͞c ϫ C57BL͞6)F 1 mice (F 1 ) were purchased from the National Cancer Institute, Frederick Cancer Research Facility (Frederick, MD). P. Ohashi (University of Toronto, Toronto) provided the MC57G fibrosarcoma cell line. The 8101 PRO1A fibrosarcoma is a progressor variant of the C57BL͞6 tumor 8101 (6) . TAM and 4-hydroxytamoxifen (4-OHTAM) were purchased from Sigma. For Western analysis, EGFP was detected by using the Living Color A.v. peptide antibody, an anti-EGFP antibody from CLONTECH, and developed by using Enhanced Chemiluminescence (Amersham Pharmacia). All oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). ; in 0.2 ml) were injected s.c. into Rag1 Ϫ/Ϫ mice or in F 1 mice treated with anti-CD8 ascites (clone YTS 169.4.2). After 2-3 wk of growth, solid tumor fragments were harvested and implanted s.c. into the F 1 mice by using a 13-gauge trochar. We observed no difference in the growth rate of uninduced tumors compared with tumors induced to express EGFP. Tumors grew in 20-50% of the F 1 mice challenged with tumor fragments. For EGFP induction, 2 mg TAM (in 0.1 ml) was injected i.p. Only the sera from mice bearing 30-to 40-day established tumors were analyzed for anti-EGFP antibodies (see Fig. 4 ; see Fig. 5 and Table 2 , which are published as supporting information on the PNAS web site, www.pnas.org). DTH was performed as described (16) .
ELISA for Measuring Anti-EGFP Antibodies. Anti-EGFP antibodies were measured as described with certain modifications (17) . The full ELISA methodology (as well as the methodology for generating the inducible EGFP vector and the inducible EGFP clone, the PCR, and detecting CD4 ϩ and CD8 ϩ T cell responses) is described in the Supporting Text, which is published as supporting information on the PNAS web site.
Results
A TAM-Regulated Cre-loxP System Induced EGFP Expression in Cancer
Cells. We used EGFP as a model tumor antigen because this antigen stimulates antibody responses in mice (17, 18) . We constructed the inducible EGFP vector (iEGFP), in which a puromycin resistance gene flanked by loxP sites separated the cytomegalovirus promoter and the EGFP gene ( Table 1 ). The puromycin resistance gene both inhibited EGFP expression and enabled the selection of cells that contained the unrecombined This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: EGFP, enhanced GFP; DTH, delayed type hypersensitivity reaction; TAM, tamoxifen; 4-OHTAM, 4-hydroxytamoxifen; MCM, MC57G cancer cell clone transfected with pAN-MerCreMer; MCME, MC57G cancer cell clone transfected with pAN-MerCreMer and iEGFP; iEGFP, inducible EGFP vector; MFI, mean fluorescence intensity. iEGFP construct. We transfected the fibrosarcoma MC57G with pAN-MerCreMer to generate the clone MC57G-MerCreMer (MCM). MerCreMer contained a Cre recombinase fused to two mutant murine estrogen receptors that regulated the recombinase activity in a TAM-dependent manner (15) . MCM was then transfected with the iEGFP construct to generate an MC57G-MerCreMer-iEGFP clone (MCME). In the absence of TAM, MCME cells were uninduced and the iEGFP gene remained unrecombined (Table 1 ). In the presence of TAM, MerCreMer recombined the iEGFP gene, causing the removal of the floxed puromycin gene and the expression of higher levels of EGFP in MCME cells.
4-OHTAM Treatment of MCME Cells Results in Site-Specific DNA
Recombination and Increased EGFP Expression in Vitro. We treated MCME cells with 200 nM of 4-OHTAM. At different times, we harvested genomic DNA and performed multiplex PCR to detect the unrecombined or recombined iEGFP gene ( Fig. 1A and Table 1 ). In the absence of 4-OHTAM, the majority of MCME cells did not recombine the iEGFP gene, whereas in the presence of 4OH-TAM, DNA recombination became apparent within 6 h. We also subjected 4-OHTAM-treated MCME cells to Western analysis for EGFP expression. Whereas multiplex PCR detected DNA recombination by 6 h, we did not detect EGFP expression until 24 h after 4-OHTAM treatment (Fig. 1B) . † The fold-increase in EGFP fluorescence above parental MCM cells was determined by the MFI of MCME cells before TAM treatment (0 h) and 4 days after TAM treatment (96 h) from three independent experiments. The fold increase is the average of three independent experiments preformed in duplicate. To quantify the frequency and level of EGFP induction, we analyzed MCME cells for EGFP fluorescence (Fig. 1C) . Although we did not detect EGFP expression by Western analysis, the uninduced MCME cells [mean fluorescence intensity (MFI) 14 .07] had Ϸ5.5-fold higher fluorescence than MCM cells (MFI 2.53). Consistent with previous observations (19) , the floxed puromycin gene and the poly(A) termination sites did not completely inhibit EGFP transcription because cells transfected with only the iEGFP vector had slightly elevated levels of EGFP fluorescence (data not shown). Within 6 h of 4-OHTAM treatment, a significant population of cells increased fluorescence, and, after 96 h, Ͼ90% of the cells fluoresced above background. At 96 h, induced MCME cells (MFI 1319.2) fluoresced 388-fold above the parental MCM clone (MFI 3.4) indicating that 4-OHTAM induced Ϸ70-fold increase in EGFP expression. These results also showed that most cells carried the recombined iEGFP gene within 96 h of 4-OHTAM treatment.
TAM Rapidly Induces High, Stable Levels of EGFP Expression in Vivo.
Rag1
Ϫ/Ϫ mice were injected with MCME cancer cells, and, 15 days later, the mice were treated with vehicle alone, 0.25 mg, 0.5 mg, 1 mg, or 2 mg of TAM i.p. for 11 days. Mice were treated with TAM because mice could metabolize TAM into more potent derivatives, e.g., 4-OHTAM (20) . We monitored changes in EGFP expression within the tumor by taking fine needle biopsies every 3 days. Fine needle biopsies were cultured in G418 for 7-10 days to kill the contaminating stroma, and EGFP induction was assessed by fluorescence cytometry. Induction of EGFP in tumors was similar in male and female mice (data not shown). In addition, we observed a dose-dependent increase in the rate at which EGFP was induced. Whereas TAM doses of 0.25-1 mg induced the greatest percentage of cells expressing high levels of EGFP at 6 days, 2 mg of TAM induced the greatest percentage of cells expressing EGFP within 3 days ( Fig. 2A) . To determine the stability of the uninduced or induced phenotype, mice were challenged with uninduced MCME tumor fragments and, at 19 days, treated the mice with 2 mg TAM or the vehicle alone for 3 days (Fig. 2B) . Three weeks after TAM treatment, the tumor cells in mice treated with TAM still expressed high levels of EGFP, indicating that the induced phenotype was stable in a growing tumor. Conversely, MCME tumors in mice treated with the control vehicle maintained low levels of EGFP fluorescence, indicating that uninduced phenotype was also stable.
Tumor-Bearing Mice Rapidly Generate High Titer Anti-EGFP Antibodies in Response to EGFP Induction. We determined whether tumorbearing mice were capable of generating an immune response that could detect an antigen induced to high levels of expression within the growing tumor. Because antibody responses against EGFP have been reported in the BALB͞c strain, we used (BALB͞c ϫ C57BL͞6)F 1 (F 1 ) mice that retained host reactivity against the EGFP antigen while remaining tolerant to the MC57G tumor (17, 18) .
First, we determined whether F 1 mice generated a cellular response to MC57 tumors expressing EGFP. We immunized mice with either EGFP-transgenic C57BL͞6 splenocytes, MCME cells induced in vitro to express high levels of EGFP, or the parental MCM cells. Whereas EGFP-expressing splenocytes induced the generation of anti-EGFP CD8 ϩ T cells in the peripheral blood, in vitro-induced MCME tumor cells and the parental MCM cell lines failed to induce a similar response (Fig.  5 ). In addition, we failed to detect IL-4 production, IFN-␥ production, or cytolytic activity in the CD8 ϩ or CD4 ϩ T cells from mice immunized with in vitro-induced MCME cells. (Data not shown). However, F 1 mice did generate high titer anti-EGFP antibodies against in vitro-induced MCME tumors (P Ͻ 0.001) by day 12 (Fig. 3B and Table 2 ). In contrast, uninduced MCME tumors (Fig. 3C) did not elicit detectable EGFP antibody titers because these titers did not differ from those of naive mice or of mice bearing the parental MCM tumors (Fig. 3A) for a similar amount of time.
Because mice generated antibodies against tumors expressing EGFP at the time of challenge, we determined whether mice bearing established tumors also generated anti-EGFP antibodies when EGFP was induced in vivo. When mice bearing uninduced MCME tumors for almost 3 wk were treated with TAM, we observed that these mice generated anti-EGFP antibodies within 2-3 wk (Fig. 3D) . Three weeks after TAM treatment, eight tumor-bearing mice in five independent experiments possessed a serum anti-EGFP antibody titer of 2,970 Ϯ 989, which was 27-to 243-fold greater than the anti-EGFP antibody serum titer of 30 in control treated mice (P Ͻ 0.001; Table 2 ). Thus, the tumor-bearing host rapidly generated antibodies against new tumor antigens.
Anti-EGFP Antibodies Undergo Class Switching and Arise in the
Context of Preexisting Anti-Tumor Antibody Responses. We characterized IgG class of these new anti-EGFP antibodies to elucidate how antibody responses may arise against new antigens. The predominant anti-EGFP antibody response was of the IgG1 subclass regardless of whether EGFP expression was induced after 3 wk of tumor growth or expressed at the time of tumor challenge (data not shown). Because antibodies can be generated to other tumor antigens, we determined whether specific antitumor antibodies existed before the EGFP antibody was detected. We incubated antigen-specific MCM cells or the nonspecific PRO1A cells with sera of mice bearing MCME tumors before or after TAM treatment. Indeed, mice generated specific IgG anti-tumor antibodies before the anti-EGFP antibody response was induced (Fig. 3E) . Preexisting, Tumor-Specific CD4 ؉ T Cell Immunity Potentiates Anti-EGFP Antibody Responses. Because both the anti-EGFP antibodies and the anti-tumor antibodies were of the IgG class, these observations suggested that CD4 ϩ T cell help existed before and was likely required for the anti-EGFP antibody response. In fact, mice treated with anti-CD4 antibody failed to make anti-EGFP antibodies, suggesting that CD4 ϩ T cells were required for an anti-EGFP antibody response (Fig. 4A) . To determine whether MCME cells induced significant anti-EGFP CD4 ϩ T cell responses, we examined whether immunity against induced MCME cells expressing high levels of EGFP conferred EGFPspecific and͞or MC57 tumor-lineage-specific T cell immunity. We compared the DTH response to the induced MCME tumor, the parental MCM tumor, or the control PRO1A tumor in mice immunized with these cell lines (Fig. 4B) . Immunity to the parental MCM cells was sufficient to induce responses to MCME cells expressing EGFP. Furthermore, mice immunized with induced MCME cells failed to elicit greater DTH responses to MCME cells expressing EGFP compared with the parental MCM cells, suggesting that the EGFP expressed by MCME cells did not induce significant CD4 ϩ T cell-mediated anti-EGFP immunity.
Because we failed to detect EGFP-specific CD4 ϩ T cell responses, we hypothesized that CD4 ϩ T cells responding to other antigens on the cancer cell provided the T cell help necessary to generate anti-EGFP antibodies. We immunized mice with the uninduced MCME tumor or an unrelated tumor PRO1A. After 12 days, we challenged these immunized mice or naive mice with tumor fragments of in vitro-induced MCME cells expressing high levels of EGFP. Mice immunized with uninduced MCME tumors generated substantial anti-EGFP antibodies within 9-12 days after challenge with the induced EGFP tumor (Fig. 4C) . In contrast, naive mice and mice immunized with the unrelated PRO1A tumor failed to generate anti-EGFP antibody responses to challenges with EGFP-expressing MCME tumors, indicating that existing tumor immunity was tumorlineage specific. Because uninduced MCME tumors expressed low levels of EGFP, we assessed whether immunization with the MC57G tumor, which is the parental tumor of the MCME tumor, also potentiated an anti-EGFP antibody response (Fig.  4C) . As with the uninduced MCME immunization, mice immunized against MC57G generated greater anti-EGFP antibody responses compared with mice immunized against PRO1A. Thus, existing tumor-associated CD4 ϩ T cell help may potentiate antibody responses against new antigens even when these antigens fail to induce specific CD4 ϩ T cell responses.
Discussion
We find that the tumor-bearing host can rapidly generate antibodies against new antigens that arise from genetic changes occurring within a growing tumor. Furthermore, our observations establish that the immune system can respond to new tumor antigens in the context of an existing anti-tumor immune response. We modeled the appearance of these antigenic variants by inducing genes with a novel Cre-loxP system. When antigen expression increased, the host rapidly generated high titer IgG antibody responses. Although the uninduced tumors expressed antigens at low levels, these tumors did not elicit detectable antibodies. Therefore, new antibody responses may recognize either newly expressed proteins or existing proteins that become overexpressed.
Preexisting CD4 ϩ T cell responses likely potentiated antibody responses to the induced antigen, because CD4 ϩ T cell responses were required but specific CD4 ϩ T cell responses to the induced antigen were not detected. Previous reports have described this mechanism of intermolecular help in which distinct molecules D) , or in vitro-induced MCME tumor fragments that expressed high levels of EGFP (B). On day 19, mice bearing uninduced MCME tumors were treated with TAM ϩ oil (D) or with oil alone (C) for 3 days. Total numbers of mice in each group are indicated in Table 2 . (E) Mice were challenged with uninduced MCME tumors, and sera was collected on day 0, day 12, day 19, day 26, and day 33. Twelve days after tumor challenge, mice were treated with oil (Mouse 1) or oil ϩ TAM (Mouse 2 and 3). At day 33, the anti-EGFP antibody titer of Mouse 1, Mouse 2, and Mouse 3 were 30, 7,290, and 2,430, respectively (summarized in Table 2 ). Sera at these times was also tested for anti-MC57 antibodies by fluorescence cytometry. Namely, MCM cells or PRO1A cells were incubated with a 1:10 dilution of serum samples, washed, and incubated with phycoerythrinconjugated goat anti-mouse IgG secondary antibody. Because anti-EGFP antibodies were detected only in Mouse 2 and 3 at day 33, these results indicate that anti-tumor antibodies preceded the anti-EGFP antibody response.
within the same cell or complex contain the helper T cell and B cell epitopes (21) (22) (23) . Thus, antibody responses may reflect genetic changes occurring within a growing tumor without the need for these antigens to induce new cellular immune responses that may be difficult to generate in a tumor-bearing host. In any case, cancer patients possess tumor-specific CD4 ϩ T cell responses (24) that may directly or indirectly induce an antibody response to a new tumor antigen.
To study antibody responses to new antigens, we used a TAM-regulated site-specific recombination method to induce antigens in established tumors. Ligand-regulated recombination has induced multiple genes in vitro and in transgenic mice (14, 25) . Cre recombinase activity does not require energy or cofactors (26) , and, therefore, Cre recombinase can efficiently recombine DNA even in a hypoxic tumor environment. Because Cre recombination is essentially irreversible, a short-term TAM treatment permanently induces gene expression, with minimal effects on the tumor-bearing host. In contrast, ligand-regulated promoters reversibly induce genes to levels proportional to the concentration of the ligand in the surrounding environment (27) . with DTH response of naive mice. †, P ϭ 0.4602 for DTH response of mice immunized with MCME-induced cells and challenged with MCM-or MCME-induced cells. ‡, P ϭ 0.1469 for DTH response of mice immunized with MCM cells and challenged with MCM-or MCME-induced cells. Numbers in parentheses indicate the total number of mice used in two independent experiments. (C) Mice were challenged with uninduced MCME tumor fragments, parental MC57G tumor fragments, or PRO1A tumor fragments. Twelve days later, mice were challenged with induced MCME tumor fragments that expressed high levels of EGFP. Data are representative of two to three independent experiments, each using two mice per group.
remains unclear whether a similar robust antibody response would develop against less immunogenic tumor-associated self antigens, such antigens when up-regulated in cancers can generate detectable antibody responses (31) . In addition, new mutations occurring during tumor progression may cause strongly immunogenic mutant antigens. Whereas passively transferred antibodies can have significant therapeutic effects (for review see ref. 1), the effect of endogenous antibodies on tumor growth remains unclear because endogenous antibodies may prevent CD8 ϩ T cell responses and may promote tumor growth (32, 33) . In any case, a patient's sera can identify new targets for cancer therapy (7) .
By analyzing the humoral immune response of cancer patients, serological analysis of recombinant cDNA expression (SEREX) has revolutionized the ability to identify the molecular and genetic nature of the target of anti-tumor antibodies (3, 34) . Some anti-tumor antibodies recognize important oncogenic proteins and͞or can be correlated with certain malignancies (35) (36) (37) . Because genetic alterations guide tumor progression, we propose that new antibody responses arising in a tumorbearing host may reflect and identify genetic changes important for cancer progression. Although cancer progression may alter immune responses against tumors, antibody responses against tumor antigens can increase with increasing tumor burden (12, 30) and, thereby, increase the likelihood of detecting a new antibody response. Therefore, serial analysis of a patient's serum may complement direct genetic analysis by providing probes to identify the genetic origin of these changes and by providing a noninvasive means for monitoring these changes that occur during tumor progression. By knowing when and what molecular changes occur during tumor growth, we may better implement therapies to combat the progressing malignancy.
